TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Median interval to first medication adjustment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatal postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Death due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Placenta expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improvement in LIPCOF, BUT and Schirmer scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in inflammation of the edge of eyelid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective improvement of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Slower rise in TNF-alpha receptor 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of postpyloric placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amphetamine exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural integrity of the collagen network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stool output (grams per hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of major cardiovascular events prevented
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall concordance between photograph‐based vs in‐person diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma profiles of morphine and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-year biochemical progression-free survival (bPFS)
Endpoint domain: Mortality/survival
Primary endpoint: variation of ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation of pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success at TOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auscultation skill levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of non-pain side effects
Endpoint domain: Adverse events/effects
Primary endpoint: reduced ejaculatory volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in IPSS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quality of life index improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cortical relay time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: bacterial colonization of the ETTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: microbial load (CFU per mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Observed radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived physical conditioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: body satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall physical self-worth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in METH craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative METH urine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAARS: Investigator‐Rated: Screening Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression‐ADHD‐Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult ADHD Quality of Life‐29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in FWS of crows' feet at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average amount eaten (grams per meal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of CIAKI and/or acute pulmonary edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improving anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reducing risk for adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Physical disability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core stability improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation of diagnosis of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worsening of physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: worsening of cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: worse global quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General cognitive index (GCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak SC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of infective complications
Endpoint domain: Adverse events/effects
Primary endpoint: hazard of death within 6 months
Endpoint domain: Mortality/survival
Primary endpoint: decrease in J-index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in M-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median plasma paracetamol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surfactant half-life (T(1/2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from RDS
Endpoint domain: Mortality/survival
Primary endpoint: Total drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functional lower limb strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VVSymQ score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPR-V(3) score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEINES-QOL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute measurements of NFLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual flow appearance timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects severity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean remaining dentine thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of PD comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of skinfolds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dp-ucMGP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma PTX3 level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative quality of recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete occlusion of GDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of GDA coil embolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of microcoils used per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASAS20 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spinal mobility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical capacity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change from baseline in IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resumption of oral intake on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of minor or major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Technical difficulty score for the surgeon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse events (hypotension and nausea)
Endpoint domain: Adverse events/effects
Primary endpoint: allogenic blood transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: coagulopathy improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Week 12 smoking abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental stress-induced platelet aggregation responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of appearance of exogenous glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: colour vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of disclosure to a partner
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement on presence of any fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean thickness of the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement on presence of SRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year survival time
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in tender point count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of doses per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 6-month drug costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUDIT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced levels of alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: red blood cell transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transmembrane Pressure (TMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Running Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median survival after enrollment
Endpoint domain: Mortality/survival
Primary endpoint: Number of admissions for CHF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Event free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Relapse-free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in Binocular Summation Scores (BiS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in functional fitness parameters
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Promotion of a more active lifestyle
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiographic recurrence (HVA > 20°)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA class improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: C(max) of etamicastat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(last) of etamicastat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(∞) of etamicastat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of severe exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: hospitalizations/ED treatments due to asthma
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: complete occlusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in micturition episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urgency episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in incontinence episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goal achievement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Methacholine PD20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of ultrasound-diagnosed intussusception
Endpoint domain: Adverse events/effects
Primary endpoint: Use of osteoporosis medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macular visual evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAP alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete resolution of BRONJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVC colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CRBSI incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: self-reported relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean costs
Endpoint domain: Resource use
Primary endpoint: Radiographic values postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in syphilis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Tidal volume (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of dose delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early postoperative plasma levels of sRAGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of CGM below 4 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean absolute relative differences in hypoglycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical accuracy in hypoglycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical score of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotective antibody levels against diphtheria and tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Booster responses to pertussis antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Injection site reactions and fever
Endpoint domain: Adverse events/effects
Primary endpoint: early mortality from donor dysfunction
Endpoint domain: Mortality/survival
Primary endpoint: amount of tricuspid valve regurgitation at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: shorter reperfusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Early Wound-Healing Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision quality
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incremental area under the curve for triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Steady-state plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(max) achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of risperidone from 0 to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal plasma zinc concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total duration of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: functional score gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calf pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gluteal pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in interleukin 6 (IL6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Active renin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: total FV intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient-rated outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ultimate cure (clinical and parasitological cure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of dying from liver disease
Endpoint domain: Mortality/survival
Primary endpoint: mean cortical healing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full weightbearing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication of P. aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase in Stenotrophomonas maltophilia
Endpoint domain: Adverse events/effects
Primary endpoint: progression to early Alzheimer's Disease (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plasma MDA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in academic productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Viral load suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arterial bradykinin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BK1-5 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue-type plasminogen activator antigen concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean morning PEF measured 5 minutes after dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced use of rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased number of episode‐free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC(0‐96h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in itch and pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in stages of ARD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: work-related vitality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: general vitality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Practical examination ankle scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practical examination knee scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes